Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Becker, M C; Wang, T H; Wisniewski, L; Wolski, K; Libby, P; Lüscher, T F; Borer, J S; Mascette, A M; Husni, M E; Solomon, D H; Graham, D Y; Yeomans, N D; Krum, H; Ruschitzka, F; Lincoff, A M; Nissen, S E (2009). Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal, 157(4):606-612.

Full text not available from this repository.

View at publisher


BACKGROUND: Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs). However, the relative cardiovascular safety of these therapies remains uncertain. METHODS: The Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION) trial will evaluate the cardiovascular safety of celecoxib, ibuprofen, and naproxen. Approximately 20,000 patients with symptomatic osteoarthritis or rheumatoid arthritis at high risk for, or with, established cardiovascular disease will be randomized in this double-blind, triple dummy, multinational, multicenter study. The primary end point is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The trial will continue until 762 primary events occur with at least 18 months follow-up. Noninferiority of any of the regimens will require a 97.5% upper CI of the hazard ratio (HR) < or =1.33 and point estimate < or =1.12 for both intent-to-treat (ITT) and modified ITT populations. CONCLUSION: PRECISION, the first study of patients with high cardiovascular risk chronically treated with a cyclooxygenase-2 selective inhibitor or nonselective NSAID, will define the relative cardiovascular safety profile of celecoxib, ibuprofen, and naproxen and provide data to help guide NSAID use for pain management for this population.


51 citations in Web of Science®
62 citations in Scopus®
Google Scholar™


Additional indexing

Contributors:PRECISION Investigators
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
Dewey Decimal Classification:610 Medicine & health
Date:April 2009
Deposited On:21 Dec 2009 12:02
Last Modified:05 Apr 2016 13:40
Free access at:Related URL. An embargo period may apply.
Publisher DOI:10.1016/j.ahj.2008.12.014
Related URLs:http://www.kardiologie.usz.ch/SiteCollectionDocuments/LehreUndForschung/publikationen/reviews/R2_Becker_MC_Rationale_design_and_governance_of_prospective_randomized_evaluation_of_celecoxib.pdf (Author)
PubMed ID:19332185

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page